Estimating the Risk of Radiocontrast-Associated Nephropathy.
Estimates of the incidence of radiocontrast-associated nephropathy vary widely and suffer from misclassification of the cause of AKI and confounding. Using the Nationwide Inpatient Sample, we created multiple estimates of the risk of radiocontrast-associated nephropathy among adult patients hospitalized in the United States in 2009. First, we stratified patients according to the presence or absence of 12 relatively common diagnoses associated with AKI and evaluated the rate of AKI between strata. Next, we created a logistic regression model, controlling for comorbidity and acuity of illness, to estimate the risk of AKI associated with radiocontrast administration within each stratum. Finally, we performed an analysis stratified by the degree of preexisting comorbidity. In general, patients who received radiocontrast did not develop AKI at a clinically significant higher rate. Adjusted only for the complex survey design, patients to whom radiocontrast was and was not administered developed AKI at rates of 5.5% and 5.6%, respectively. After controlling for comorbidity and acuity of illness, radiocontrast administration associated with an odds ratio for AKI of 0.93 (95% confidence interval, 0.88 to 0.97). In conclusion, the risk of radiocontrast-associated nephropathy may be overstated in the literature and overestimated by clinicians. More accurate AKI risk estimates may improve clinical decision-making when attempting to balance the potential benefits of radiocontrast-enhanced imaging and the risk of AKI.
Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California ewilhelm@stanford.edu.
Emilee
E
Wilhelm-Leen
Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California.
Maria E
ME
Montez-Rath
Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California.
Glenn
G
Chertow
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000453:epidemiology*; D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D018570:Risk Assessment
D003287:Contrast Media
acute renal failure; nephrotoxicity; outcomes
Radiology. 2014 Dec;273(3):714-25
25203000
Arch Intern Med. 1985 Jan;145(1):87-9
3882071
AJR Am J Roentgenol. 2008 Aug;191(2):376-82
18647905
AJR Am J Roentgenol. 2010 Aug;195(2):414-22
20651198
Med J Aust. 1991 Sep 2;155(5):329-32
1895978
Semin Dial. 2005 May-Jun;18(3):239-42
15934971
J Am Soc Nephrol. 2004 Sep;15(9):2462-8
15339996
AJR Am J Roentgenol. 2011 May;196 (5):1094-101
21512075
Am J Kidney Dis. 2002 Aug;40(2):236-42
12148095
Radiology. 2014 Apr;271(1):65-73
24475854
Radiology. 2013 Apr;267(1):106-18
23360742
AJR Am J Roentgenol. 2009 Mar;192(3):711-8
19234268
Radiology. 2013 Apr;267(1):119-28
23319662
J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90
8410092
Am J Kidney Dis. 2002 May;39(5):930-6
11979336
Neurology. 2005 May 24;64(10):1805-6
15911820